The first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist, which it is hoped will treat chronic pain without the potential for abuse. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and… Read More
TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory… Read More
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and… Read More
Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More
A type 1 diabetes patient has been successfully treated using chemically induced pluripotent stem-cell-derived islets (CiPSC islets). The Phase I trial is the first ever example of a person with the disease being treated using cells that were extracted from their own body. The… Read More
NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More
QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002. The data was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the release of clinical study results that led some media titles to ask… Read More
Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format. With the release of clinical… Read More
Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More
Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60. FTD(GRN), which… Read More
News round-up for 2-6 September by DDW Senior Digital Content Editor Diana Spencer. With the release of clinical study results that led some media titles to ask if semaglutide could be a ‘fountain of youth’, this week our news highlights focus on clinical trials at a variety of… Read More
Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD) study will be conducted… Read More
CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More
The first subjects have been dosed in two separate Phase I clinical trials evaluating the safety, tolerability, and pharmacokinetics of Sionna Therapeutics’ SION-719 and SION-451 in healthy volunteers. SION-719 and SION-451 are product candidates from the company’s series of highly potent nucleotide-binding domain 1 (NBD1) stabilisers… Read More
The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More
